{
    "2018-07-02": [
        [
            {
                "time": "",
                "original_text": "医药行业：把握行业新秩序下的龙头新趋势",
                "features": {
                    "keywords": [
                        "医药",
                        "行业",
                        "龙头",
                        "趋势"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "[买入评级]泰格医药(300347)：业绩符合预期 方达港股上市进程稳步推进",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "买入评级",
                        "业绩",
                        "方达",
                        "港股",
                        "上市"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "中金医药月度7+5组合：7月组合",
                "features": {
                    "keywords": [
                        "中金医药",
                        "月度组合",
                        "7+5",
                        "7月"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "[增持评级]泰格医药(300347)半年度业绩预告点评：内生持续高增长 汇兑损益或缩窄",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "增持评级",
                        "半年度",
                        "业绩",
                        "内生增长",
                        "汇兑损益"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}